Merck & Co., Inc. (MRK) belonging to the Medical sector has declined -0.44% and closed its last trading session at $63.9.
The company reported its EPS on 02/02/2017. Currently, the stock has a 1 Year Price Target of $68.75.
The consensus recommendation, according to Zacks Investment research, is 1.68. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1.68 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.68 and 1.86 respectively.
For the Current Quarter, the growth estimate for Merck & Co., Inc. is -5.6%, while for the Next Quarter the stock growth estimate is -5.4%.
In the past 5 years, the stock showed growth of -0.23% per annum. While for the next 5 years, the growth estimate is 6.64%.
The Company got Initiated by Bryan Garnier on 13-Jan-17 to Buy.
Insider Trades for Merck & Co., Inc. show that the latest trade was made on 26 Feb 2017 where Graddick-Weir (Mirian M), the Officer completed a transaction type “Buy” in which 16995 shares were traded at a price of $65.85.
6 Insider Sales transactions were made totaling 389423 shares traded.
20 analysts projected Price Targets for Merck & Co., Inc.. The analysts believe that the company stock price could grow as high as $85. The Low Price target projection by analysts is $52 and the Mean Price Target is $68.75.
Merck & Co., Inc. (MRK) has the market capitalization of $175.44 Billion. The company rocked its 52-Week High of $66.8 on Mar 1, 2017 and touched its 52-Week Low of $52.1 on Mar 21, 2016.
The stock has Return on Assets (ROA) of 4 percent. Return on Equity (ROE) stands at 9.2% and Return on Investment (ROI) of 6.2 percent.
The stock is currently showing YTD performance of 9.33 Percent. The company has Beta Value of 0.84 and ATR value of 0.79. The Weekly and Monthly Volatility stands at 1.28% and 1.16%.